Supernus plunges on trial setback for depression therapy; Cantor downgrades
Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...
中国日报网3h
Insomnia, depression treatment a click away
A digital-based therapy using a mobile application with recording and analytic functions can relieve symptoms of insomnia and ...
Scientific American2d
New Psychotherapies That Focus on Positive Experiences Could Better Treat Depression and Anxiety
Craske and her colleagues hypothesized that targeting this mechanism for reward sensitivity could help strengthen affected ...
News94h
Therapy Thursday: How stress, depression and anxiety can impact heart health
In today's Therapy Thursday, therapist Kyann Mitchner with Sunbeam Family Services discusses the physical impact stress, ...
Supernus' depression treatment fails mid-stage trial, shares plunge
Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.
Pharmaceutical Technology on MSN1d
Supernus’s stock sinks after depression drug fails trial
The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Bill would require Alabama’s Medicaid to cover postpartum depression screenings
“This bill would require the Alabama Medicaid Agency to cover screening and would also regulate how Medicaid covers prescription drugs used to treat postpartum depression,” the legislation states.
Can depression speed up aging? Scientists warn of a 30% higher health risk
Depression impacts overall health, accelerating the onset of chronic conditions by 30%. A study found that those with a ...
App-based insomnia therapy found to cut depression rate among Hong Kong youth
Study looked into digital cognitive behavioural therapy for insomnia among young people in first such clinical research in Asia.
The Pharma Letter15h
Depression failure sends Supernus shares downwards
US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
A new solution may help reduce therapy 'dropouts'
Seeking mental health help is a significant step, but that first intake session can often feel more like paperwork than ...